Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres

Launched by ASTRAZENECA · Jun 11, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at patients with severe asthma who have received a medication called tezepelumab. The researchers want to gather information from medical records to understand how patients are doing after starting this treatment. They will review the health records of about 200 patients who began taking tezepelumab between January 1, 2023, and July 19, 2023, at various healthcare centers in the UK. By looking at their past and current health data, the study aims to see how effective this treatment is over time.

To be eligible for the trial, patients must be 18 years or older and have started their first dose of tezepelumab within the specified dates. Importantly, if patients have used another asthma biologic treatment in the year before starting tezepelumab, they won’t be included in the study. Participants won’t need to do anything extra since the information is collected from their existing medical records, and their treatment choices will remain unaffected. The study will follow these patients for a year to see how they respond to the medicine and to learn more about managing severe asthma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who received their first dose of tezepelumab between 1st January 2023 and 19th July 2023 (TPAP cohort) or between 20th July 2023 and 31st March 2024 (post-TPAP cohort)
• • Patients aged ≥18 years at index
• Exclusion Criteria:
• • Patients who received any biologic drug for the treatment of asthma in a clinical trial at any time during the 52 weeks prior to the index date.